The outcomes oftympanoplasty in the elderly are generally /10 different from those in the young. Althoug h some reports sugges t that hearin g results were not as good in patients older than 60, the instance ofgraftfailure in these pati ents did not differ greatly by age.
Introduction
Since 1958, the author has perfo rmed 1,423 tympanop lasties, with and without mastoidectomy, for patients with chronic ear disease (n=853) and cholestea toma (n=570) in his private prac tice. In addition , the author has staffed at least 2,200 otologic cases at the State University of New York at Brooklyn and at the Indiana University Medica l Schoo l.in Indianapo lis.
This article reviews the preoperative evaluation of the elderly patient-including the otologic examination and tempora l bone computed tomography (CT)-and the surgical techniques for the various pathologies.
Aging and the ear Physiologic changes related to advancing age involve both the peripheral and central auditory pathwa ys. Degener ative changes can be seen in the pinna , and atroph y can be seen within the ear canal in the skin, appendages, and the eardrum. In the middle ear , nonspecific osteitis and sclerosis of the ossicles can occur. In the inner ear, atrophy of hair cells and supporting cells of cochlea can be seen. In addition, arteriosclerotic dege nera tion of epithelial tissue and inner ear vessels-including the organ of Corti , basilar membrane, and the stria vasc ularis-may occur, leading to dege neration of the coch lear nerve and a loss of spiral ganglion cells. The four types of patho logic change s in presbyc usis as described by Schuknecht are sensory, neural , metabolic, and mechanical.' Other signs are brain stem atrophy, ganglion cell degeneration at all the principal stations of central auditory pathways, particularly in the ventral cochlear nuclei and the medial geniculate body, and brain atroph y with sharp reductions of cortical cells , incl uding those in the auditory radiation s. Our understanding of age-related problems can be hindered by the adverse and cumul ati ve effects of infection, noise, drugs, traumatic injuries, and arteriosclerosis. These factor s make it more difficult to identify the behavioral and physical changes that are the resu lt of aging excl usively.
The goal of tympanomastoid surgery is to obtain a dry ear by eradicating middle ear and mastoid infection and to reconst ruct the sound transmission mechanism. The outcomes of tympanoplasty in the elderly are generally no different from those in the young. Outco mes depend on several factors, including the extent and severity of middle ear and mastoid disease; the presence of tympanic membrane perforation, polypoid tissue , or cholesteatoma; eustachian tube funct ion ; preoperative hearing level (air and bone conduction, speech reception thre shold , speech discrimin ation score); the experience of the surgeon; and the type of tympanoplasty performed.
Preoperative evaluation
During the preoperative assessment, the physician should determine the duration of the chronic ear prob lem and the patient ' s smoking and alcoho l status, medication history , and history of allergies and other concomitant illnesses, such as cardiovascular diseases, diabetes mellit us, renal dysfunction, chronic obstructive pulmonary disease, and dementia.
A comp lete head and neck examination should include an otomicroscopic assess ment and the recor d should ENT-Ear, Nose & Throat Journal" July 1999 document the indication for ear surgery, be it chronic tympanic membrane perforation, chronic polypoid otitis media , mastoid infection, cholesteatoma, etc . The ear should be cleaned meticulously to minimize the risk of infection prior to surgery.
While the patient performs Valsalva's maneuver, the physician should attempt to detect any movement of the drum remnant or polypoid tissue or any hissing sound from the perforation or from between the polypoid tissue and the secretions, which would indicate that the eustachian tube might be anatomically open .
Weber's test and Rinne's test should be performed prior to an audiometric evaluation, which should include an airbone conduction study, speech reception and discrimination tests, and tympanometry.
Axial and coronal CT images of the temporal bone help determine the extent of the disease. CT is not necessary for patients with a chronic but dry, stable perforation who will reliably comply with a followup schedule.
Depending on the results of the history and physical examination, the physician might also order further preoperative tests, such as an electrocardiogram, chest x-ray, complete blood count, urinalysis, or a detailed workup for concomitant disease. It is also critical to ascertain how well the patient can tolerate general or local anesthesia. As always, the risks and benefits of surgery should be explained to the patient and family.
Surgical techniques
The type of surgical technique employed depends on the physician's training, experience, and personal preference.
In cases of simple dry tympanic membrane perforation, the transcanal or endaural incision approach is preferred." In cases of chronic diffuse polypoid otomastoiditis, the recommended technique is a postauricular approach with a posterior vascular strip incision, tympanomastoidectomy with the canal wall up, fascia graft, and ossicular reconstruction. Ossicular reconstruction is performed with the incus remnant, malleus head, and a cartilage graft from the tragus or auricle. The surgeon can sculpt the ossicle from the mastoid cortex or from the suprameatal spine of Henle with a 3-mm chisel at the start of the surgery. A surgeon can also implant a total or partial ossicular replacement prosthesis covered with cartilage, although some of these devices extrude with passage of time (4-5 yr) .
In cases of attic polyps and cholesteatoma localized to the attic and epitympanum, the surgeon can choose the modified endaural approach and atticotomy (Bondy operatiori'), followed by a fascia graft. In cases of extensive cholesteatoma of the attic, middle ear , and mastoid, the surgeon might prefer a postauricular incision, posterior vascular strip incision, and tympanomastoidectomy. This can be accomplished with the atticotympanotomy technique" or the flexible/intact bridge tympanomas-Volume 78, Number 7 toidectomy technique.' After the cholesteatoma is removed, the surgeon may perform ossicular reconstruction.
In cases of extensive cholesteatoma, with complications such as an extradural abscess or labyrinthine fistula, the surgeon may choose a postauricular approach, with the canal wall down and a fascia graft to the drum area , sealing off the middle ear and open mastoid cavity with a meatoplasty. The cholesteatoma matrix over the fistula is not removed.
During those rare occasions when all of the cholesteatoma cannot be safely removed from a deep sinus tympani, the surgeon will perform a radical mastoidectomy and meatoplasty. The removal of a cholesteatoma from the sinus tympani can be accomplished through a retrofacial approach.v"However, this procedure increases the risk of injury to the facial nerve and posterior semicircular canal.
In younger patients, the canal-wall-up technique is used, and a second-look exploration is advised. A Wullstein or Buckingham mirror or rigid otoendoscope is helpful for inspecting around the corner and in other hard-to -see areas . In some cases, the attic defect or a part of the posterior canal wall can be reconstructed -with tragus or conchal cartilage. In younger patients, the posterior canal wall can be reconstructed with the cartilage palisade technique.s"
The sinus tympani is the most difficult and challenging area in tympanomastoid surgery in terms of removing a cholesteatoma. Every effort should be made to ensure that tympanomastoid surgery in the elderly can be completed in a single operation.
Discussion
Tympanoplasty in patients older than 60 was previously considered to be inadvisable because of the high incidence of graft failure and the greater risk of pulmonary, cardiovascular, and other complications. Improvements in general anesthetic care and technique have greatly reduced the incidence of anesthesia-related complications. Surgery can be performed more safely than ever before. But even so, careful patient selection is an important factor in the outcome.
The degree of improvement in hearing following tympanoplasty in the over-60 group of patients is still somewhat controversial. Some otolaryngologists believe that improvements in older patients are not as good as those in younger patients .'?"
The primary factors that influence posttympanoplasty hearing results are the size and location of the tympanic membrane perforation, the extent of the structural and sclerotic changes in the ossicles, the extent of the inflammatory change, the presence of infection at the time of surgery, tubal function , the type of tympanoplasty performed, the material used for the drum and ossicular reconstruction, the Silas tic sheeting, the extent of the 485 
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